Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,351 total articles
DocuSign is trading near its 52-week low but shows signs of a structural rebound: a newly launched Intelligent Agreement Management (IAM) product with $350M ARR in 18 months, attractive free cash flow relative to market cap, improving technical momentum, and heavy short interest that could accelerate squeezes on positive news. We reiterate Buy with…
DXC's stock is cheap on traditional metrics (P/E ~5.3, EV/EBITDA ~2.5) and the company produces meaningful free cash flow. Recent leadership signals and sector tailwinds (hybrid cloud, security, sovereign cloud) create a favorable read-across from new hires into sales execution and margin recovery. This trade targets a mid-term rebound toward $15.5…
Blackstone Senior Floating Rate 2027 Term Fund (BSL) is my top BDC/closed-end pick right now: sub-1.0 PB, near $13.08 per share, a monthly distribution and positive technicals create an asymmetric risk/reward for a mid-term buy. I lay out an entry at $13.05, a stop at $12.30 and a target at $14.50 across a 45-trading-day horizon to capture the ex-d…
Rogers (RCI) looks attractively priced on several measures: market cap ~$20.3B, a PE of 3.65 and a 4.34% yield. Management’s messaging at the AGM and the latest annual filing point to improved free cash flow; paired with a recent debt refinancing and a manageable technical setup, this creates a tradeable long setup for the next 45 trading days.
After a period of skepticism, the evidence stacking up around Advanced Micro Devices (AMD) — big AI customer wins, robust free cash flow, low leverage, and clear technical momentum — has me moving from very bearish to confidently bullish for a defined mid-term trade. This idea lays out the entry, stop, targets, catalysts, and risks for a mid-term (…
Starbucks has shown the first clear signs of transaction-led momentum under CEO Brian Niccol. With Q2 FY26 earnings on 04/28/2026 the market is starting to reward operational improvement. This is a structured swing trade that buys that sentiment while protecting against a negative print or renewed China weakness.
After reassessing signals from demand, manufacturing traction and short-covering dynamics, I'm upgrading Intel to a tactical buy into the Q1 print. The balance of catalysts (14A adoption news, AI-driven server demand, and margin recovery) outweighs the near-term risks, but the position should be managed with a strict stop and a defined time horizon…
Beasley Broadcast Group has moved from balance-sheet risk to a potential recovery story after a package of exchange and tender offers plus asset sales that management expects will cut debt roughly in half. With trailing adjusted EBITDA improving, a tiny public float, and sharply higher share price momentum, BBGI offers a high-risk, high-reward swin…
Archrock (AROC) offers a blend of secular demand exposure to natural gas compression and improving capital returns. At $36.43 the stock trades with a mid-teens upside to our near-term target on an EV/EBITDA ~10 and a 2.3% yield. We lay out a precise entry, stop and target along with catalysts and risks.
Microsoft plunged ~10.7% into the close and opened lower on 04/23/2026. The sell-off looks indiscriminate relative to Microsoft's cash generation, profitability, low leverage and stake in AI upside. This trade idea lays out an entry at $422.24, stop at $395.00 and a primary target of $500.00 for a mid-term swing (45 trading days) with clear risk co…
Salesforce looks materially undervalued given its AI product momentum, strong free cash flow (~$14.4B) and light leverage (debt/equity ~0.24). I outline a long trade with entry at $178.00, a $165 stop and a $230 target over a mid-term 45 trading day horizon, plus the setup that would change my view.
CSX reported Q1 results on 04/22/2026 that beat on EPS ($0.43 vs. $0.39) while revenue came in roughly flat at $3.48B. With a 32% operating margin in FY2025, improving intermodal volumes, a rising dividend and disciplined capital allocation, CSX looks positioned for multi-year earnings expansion. This trade idea offers a long entry at $45.35, a pro…
Rogers' rally after its latest earnings release appears driven more by headline relief than by a durable improvement in key operating fundamentals. With limited fresh positive data available, a disciplined short targeting a reversion toward prior trading ranges offers asymmetric risk-reward. This trade uses precise entry, stop and target levels and…
SpaceX’s IPO changes the calculus for independent small-to-medium launch providers. Rocket Lab (RKLB) faces intensified pricing pressure, customer concentration risk, and lost strategic optionality as a vertically integrated SpaceX leverages scale, cadence, and Starship capacity. This trade idea lays out a mid-term (45 trading days) short with conc…
Snowflake reported a strong quarter but face-downside from macro and legal headlines has pushed the stock back toward 52-week lows. Fundamentals and AI-driven demand argue for upside; valuation and a class-action/legal overhang justify a disciplined entry with a clear stop. This trade is a mid-term swing designed to capture mean-reversion into impr…
Anteris Technologies could swing materially higher if DurAVR's PARADIGM program delivers positive clinical and regulatory signals. This trade idea lays out a disciplined long with entry, target and stop, time horizon, catalysts, and the downside scenarios that would invalidate the thesis.
Airbus is benefiting from a surging order book, yet a persistent delivery bottleneck and stretched supply chain are keeping revenue and cash conversion on the sidelines. Technicals and short-interest dynamics suggest an elevated probability of a mid-term pullback. This is a tactical short idea designed to profit from delivery disappointment and sen…
Kraken Robotics (KRKNF) has moved from a small, high-risk developer to a company booking multi-million-dollar repeat contracts and reporting meaningful margin expansion. At a market cap of $1.93B the stock has already priced growth; however, recent wins, a $20M equity raise and a 175% jump in quarterly revenue suggest the business is now materially…
Discovery Silver (DSVSF) trades at ~$7.41 with a $6.01B market cap. If the market treats a single major deposit as worth the whole company, upside is real. This trade idea lays out an entry, stop, and target with catalysts, valuation framing and balanced risks.
Toast is a vertically integrated restaurant software and payments platform that just produced record free cash flow while the stock trades well below its 52-week high. This trade idea targets a mid-term swing: a buy near $29.50 with a $40 target and a $25 stop, banking on FCF strength, >160k locations and an attractive EV-to-ARR setup to drive a re…
Adobe remains one of the highest-quality software franchises in the market. With a resilient Creative Cloud ecosystem, recurring revenue, and expanding margin optionality, a pullback creates an asymmetric opportunity. This trade idea outlines a mid-term buy with clear entry, stop, and target levels and practical reasons to own the stock into cataly…
Global Ship Lease (GSL) offers a compelling mix of current income and upside. The company sits on $2.24 billion of contracted revenue (3.6 years including options), pays a $0.625 quarterly dividend (annualized $2.50) and yields roughly 6% at current levels. With a relatively modest market cap of $1.37 billion, a fleet of 71 containerships under lon…
<p>Duolingo has reset priorities from near-term monetization back to user growth. That shift dented guidance and the stock in early 2026, but it also buys time to improve engagement and product-led conversion. At current multiples and a market cap under $5 billion, the risk/reward looks asymmetric for investors willing to hold into 2027 if manageme…
Cartesian Therapeutics is an under-the-radar clinical-stage immuno-oncology name running a Phase 3 program that, if positive, could validate mRNA-delivered CAR-T as a scalable alternative to autologous cell therapy. This trade idea lays out a directional long trade sized for high-risk biotech exposure, a clear entry at $6.50, a primary target at $1…
KKR is a capital-allocation machine whose fee-bearing business and recent realizations create a path for earnings compounding. The stock has reset from last year's highs and now trades at $105.93 with a market cap near $95B. We initiate a tactical long with a $105.93 entry, $95 stop and $130 target over a 180-trading-day horizon, citing deal flow, …
